- Home
- HRZN vs SAGE Comparison
HRZN vs SAGE Comparison
Compare HRZN & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRZN
- SAGE
- Stock Information
- Founded
- HRZN 2008
- SAGE 2010
- Country
- HRZN United States
- SAGE United States
- Employees
- HRZN N/A
- SAGE N/A
- Industry
- HRZN Finance/Investors Services
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- HRZN Finance
- SAGE Health Care
- Exchange
- HRZN Nasdaq
- SAGE Nasdaq
- Market Cap
- HRZN 396.1M
- SAGE 462.2M
- IPO Year
- HRZN 2010
- SAGE 2014
- Fundamental
- Price
- HRZN $9.42
- SAGE $5.64
- Analyst Decision
- HRZN Sell
- SAGE Hold
- Analyst Count
- HRZN 5
- SAGE 20
- Target Price
- HRZN $9.63
- SAGE $12.83
- AVG Volume (30 Days)
- HRZN 476.8K
- SAGE 792.3K
- Earning Date
- HRZN 10-29-2024
- SAGE 10-29-2024
- Dividend Yield
- HRZN 14.16%
- SAGE N/A
- EPS Growth
- HRZN N/A
- SAGE N/A
- EPS
- HRZN N/A
- SAGE N/A
- Revenue
- HRZN $104,553,000.00
- SAGE $106,399,000.00
- Revenue This Year
- HRZN N/A
- SAGE N/A
- Revenue Next Year
- HRZN $7.48
- SAGE $122.78
- P/E Ratio
- HRZN N/A
- SAGE N/A
- Revenue Growth
- HRZN N/A
- SAGE 837.60
- 52 Week Low
- HRZN $9.07
- SAGE $4.62
- 52 Week High
- HRZN $13.73
- SAGE $28.26
- Technical
- Relative Strength Index (RSI)
- HRZN 44.15
- SAGE 46.32
- Support Level
- HRZN $9.27
- SAGE $5.42
- Resistance Level
- HRZN $9.37
- SAGE $5.83
- Average True Range (ATR)
- HRZN 0.11
- SAGE 0.37
- MACD
- HRZN 0.06
- SAGE 0.11
- Stochastic Oscillator
- HRZN 100.00
- SAGE 79.84
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services and sustainability industries.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.